Novel Epac fluorescent ligand reveals distinct Epac1 vs. Epac2 distribution and function in cardiomyocytes

Laëtitia Pereira, Holger Rehmann, Dieu Hung Lao, Jeffrey R. Erickson, Julie B C Bossuyt, Ju Chen, Donald M Bers

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Exchange proteins directly activated by cAMP (Epac1 and Epac2) have been recently recognized as key players in β-adrenergic-dependent cardiac arrhythmias. Whereas Epac1 overexpression can lead to cardiac hypertrophy and Epac2 activation can be arrhythmogenic, it is unknown whether distinct subcellular distribution of Epac1 vs. Epac2 contributes to differential functional effects. Here, we characterized and used a novel fluorescent cAMP derivate Epac ligand 8-[Pharos-575]-2′ -O-methyladenosine-3′,5′-cyclic monophosphate (ℙ-O-Me-cAMP) in mice lacking either one or both isoforms (Epac1-KO, Epac2-KO, or double knockout, DKO) to assess isoform localization and function. Fluorescence of ℙ-O-Me-cAMP was enhanced by binding to Epac. Unlike several Epacspecific antibodies tested, ℙ-O-Me-cAMP exhibited dramatically reduced signals in DKO myocytes. In WT, the apparent binding affinity (Kd = 10.2 ± 0.8 μM) is comparable to that of cAMP and nonfluorescent Epac-selective agonist 8-(4-chlorophenylthio)-2-O-methyladenosine-3′-,5′-cyclicmonophosphate (OMe-CPT). ℙ-O-MecAMP readily entered intact myocytes, but did not activate PKA and its binding was competitively inhibited by OMe-CPT, confirming its Epac specificity. ℙ-O-Me-cAMP is a weak partial agonist for purified Epac, but functioned as an antagonist for four Epac signaling pathways in myocytes. Epac2 and Epac1 were differentially concentrated along T tubules and around the nucleus, respectively. Epac1-KO abolished OMe-CPT-induced nuclear CaMKII activation and export of transcriptional regulator histone deacetylase 5. In conclusion, Epac1 is localized and functionally involved in nuclear signaling, whereas Epac2 is located at the T tubules and regulates arrhythmogenic sarcoplasmic reticulum Ca leak.

Original languageEnglish (US)
Pages (from-to)3991-3996
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume112
Issue number13
DOIs
StatePublished - Mar 31 2015

Fingerprint

Cardiac Myocytes
Muscle Cells
Ligands
Protein Isoforms
Calcium-Calmodulin-Dependent Protein Kinase Type 2
Histone Deacetylases
Cardiomegaly
Sarcoplasmic Reticulum
Adrenergic Agents
Transcriptional Activation
Cardiac Arrhythmias
Fluorescence
Antibodies
Proteins
2'-O-methyladenosine
3'-O-methyladenosine

Keywords

  • Cardiomyocytes
  • Epac1
  • Epac2
  • Fluorescence
  • Localization

ASJC Scopus subject areas

  • General

Cite this

Novel Epac fluorescent ligand reveals distinct Epac1 vs. Epac2 distribution and function in cardiomyocytes. / Pereira, Laëtitia; Rehmann, Holger; Lao, Dieu Hung; Erickson, Jeffrey R.; Bossuyt, Julie B C; Chen, Ju; Bers, Donald M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 13, 31.03.2015, p. 3991-3996.

Research output: Contribution to journalArticle

@article{87dd92c5ed2b4b879180de1739765fc2,
title = "Novel Epac fluorescent ligand reveals distinct Epac1 vs. Epac2 distribution and function in cardiomyocytes",
abstract = "Exchange proteins directly activated by cAMP (Epac1 and Epac2) have been recently recognized as key players in β-adrenergic-dependent cardiac arrhythmias. Whereas Epac1 overexpression can lead to cardiac hypertrophy and Epac2 activation can be arrhythmogenic, it is unknown whether distinct subcellular distribution of Epac1 vs. Epac2 contributes to differential functional effects. Here, we characterized and used a novel fluorescent cAMP derivate Epac ligand 8-[Pharos-575]-2′ -O-methyladenosine-3′,5′-cyclic monophosphate (ℙ-O-Me-cAMP) in mice lacking either one or both isoforms (Epac1-KO, Epac2-KO, or double knockout, DKO) to assess isoform localization and function. Fluorescence of ℙ-O-Me-cAMP was enhanced by binding to Epac. Unlike several Epacspecific antibodies tested, ℙ-O-Me-cAMP exhibited dramatically reduced signals in DKO myocytes. In WT, the apparent binding affinity (Kd = 10.2 ± 0.8 μM) is comparable to that of cAMP and nonfluorescent Epac-selective agonist 8-(4-chlorophenylthio)-2-O-methyladenosine-3′-,5′-cyclicmonophosphate (OMe-CPT). ℙ-O-MecAMP readily entered intact myocytes, but did not activate PKA and its binding was competitively inhibited by OMe-CPT, confirming its Epac specificity. ℙ-O-Me-cAMP is a weak partial agonist for purified Epac, but functioned as an antagonist for four Epac signaling pathways in myocytes. Epac2 and Epac1 were differentially concentrated along T tubules and around the nucleus, respectively. Epac1-KO abolished OMe-CPT-induced nuclear CaMKII activation and export of transcriptional regulator histone deacetylase 5. In conclusion, Epac1 is localized and functionally involved in nuclear signaling, whereas Epac2 is located at the T tubules and regulates arrhythmogenic sarcoplasmic reticulum Ca leak.",
keywords = "Cardiomyocytes, Epac1, Epac2, Fluorescence, Localization",
author = "La{\"e}titia Pereira and Holger Rehmann and Lao, {Dieu Hung} and Erickson, {Jeffrey R.} and Bossuyt, {Julie B C} and Ju Chen and Bers, {Donald M}",
year = "2015",
month = "3",
day = "31",
doi = "10.1073/pnas.1416163112",
language = "English (US)",
volume = "112",
pages = "3991--3996",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "13",

}

TY - JOUR

T1 - Novel Epac fluorescent ligand reveals distinct Epac1 vs. Epac2 distribution and function in cardiomyocytes

AU - Pereira, Laëtitia

AU - Rehmann, Holger

AU - Lao, Dieu Hung

AU - Erickson, Jeffrey R.

AU - Bossuyt, Julie B C

AU - Chen, Ju

AU - Bers, Donald M

PY - 2015/3/31

Y1 - 2015/3/31

N2 - Exchange proteins directly activated by cAMP (Epac1 and Epac2) have been recently recognized as key players in β-adrenergic-dependent cardiac arrhythmias. Whereas Epac1 overexpression can lead to cardiac hypertrophy and Epac2 activation can be arrhythmogenic, it is unknown whether distinct subcellular distribution of Epac1 vs. Epac2 contributes to differential functional effects. Here, we characterized and used a novel fluorescent cAMP derivate Epac ligand 8-[Pharos-575]-2′ -O-methyladenosine-3′,5′-cyclic monophosphate (ℙ-O-Me-cAMP) in mice lacking either one or both isoforms (Epac1-KO, Epac2-KO, or double knockout, DKO) to assess isoform localization and function. Fluorescence of ℙ-O-Me-cAMP was enhanced by binding to Epac. Unlike several Epacspecific antibodies tested, ℙ-O-Me-cAMP exhibited dramatically reduced signals in DKO myocytes. In WT, the apparent binding affinity (Kd = 10.2 ± 0.8 μM) is comparable to that of cAMP and nonfluorescent Epac-selective agonist 8-(4-chlorophenylthio)-2-O-methyladenosine-3′-,5′-cyclicmonophosphate (OMe-CPT). ℙ-O-MecAMP readily entered intact myocytes, but did not activate PKA and its binding was competitively inhibited by OMe-CPT, confirming its Epac specificity. ℙ-O-Me-cAMP is a weak partial agonist for purified Epac, but functioned as an antagonist for four Epac signaling pathways in myocytes. Epac2 and Epac1 were differentially concentrated along T tubules and around the nucleus, respectively. Epac1-KO abolished OMe-CPT-induced nuclear CaMKII activation and export of transcriptional regulator histone deacetylase 5. In conclusion, Epac1 is localized and functionally involved in nuclear signaling, whereas Epac2 is located at the T tubules and regulates arrhythmogenic sarcoplasmic reticulum Ca leak.

AB - Exchange proteins directly activated by cAMP (Epac1 and Epac2) have been recently recognized as key players in β-adrenergic-dependent cardiac arrhythmias. Whereas Epac1 overexpression can lead to cardiac hypertrophy and Epac2 activation can be arrhythmogenic, it is unknown whether distinct subcellular distribution of Epac1 vs. Epac2 contributes to differential functional effects. Here, we characterized and used a novel fluorescent cAMP derivate Epac ligand 8-[Pharos-575]-2′ -O-methyladenosine-3′,5′-cyclic monophosphate (ℙ-O-Me-cAMP) in mice lacking either one or both isoforms (Epac1-KO, Epac2-KO, or double knockout, DKO) to assess isoform localization and function. Fluorescence of ℙ-O-Me-cAMP was enhanced by binding to Epac. Unlike several Epacspecific antibodies tested, ℙ-O-Me-cAMP exhibited dramatically reduced signals in DKO myocytes. In WT, the apparent binding affinity (Kd = 10.2 ± 0.8 μM) is comparable to that of cAMP and nonfluorescent Epac-selective agonist 8-(4-chlorophenylthio)-2-O-methyladenosine-3′-,5′-cyclicmonophosphate (OMe-CPT). ℙ-O-MecAMP readily entered intact myocytes, but did not activate PKA and its binding was competitively inhibited by OMe-CPT, confirming its Epac specificity. ℙ-O-Me-cAMP is a weak partial agonist for purified Epac, but functioned as an antagonist for four Epac signaling pathways in myocytes. Epac2 and Epac1 were differentially concentrated along T tubules and around the nucleus, respectively. Epac1-KO abolished OMe-CPT-induced nuclear CaMKII activation and export of transcriptional regulator histone deacetylase 5. In conclusion, Epac1 is localized and functionally involved in nuclear signaling, whereas Epac2 is located at the T tubules and regulates arrhythmogenic sarcoplasmic reticulum Ca leak.

KW - Cardiomyocytes

KW - Epac1

KW - Epac2

KW - Fluorescence

KW - Localization

UR - http://www.scopus.com/inward/record.url?scp=84961374070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961374070&partnerID=8YFLogxK

U2 - 10.1073/pnas.1416163112

DO - 10.1073/pnas.1416163112

M3 - Article

C2 - 25829540

AN - SCOPUS:84961374070

VL - 112

SP - 3991

EP - 3996

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 13

ER -